METTL25

Across TCGA pan-cancer cohorts, METTL25 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated METTL25 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher METTL25 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated METTL25 expression acts as an unfavorable survival marker.

READ, SKCM, and LGG are the cancer types where METTL25 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.111	0.919	<.001	30	view →
SKCM	DFS	Median	All	0.174	0.764	<.001	24	view →
LGG	OS	Median	All	0.034	0.909	<.001	12	view →
BLCA	DFS	Median	IV	0.090	0.469	.009	12	view →
LIHC	DFS	Median	All	0.142	0.555	.019	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

METTL25–READ (OS)

Open the READ breakdown →